Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

Nucleosides, Nucleotides and Nucleic Acids

Volumn 27, Issue 6-7, 2008, Pages 720-725

  Giovannetti, E ^a,b   Laan, A C ^a   Vasile, E ^c   Tibaldi, C ^c   Nannizzi, S ^b   Ricciardi, S ^b   Falcone, A ^c   Danesi, R ^b   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

^c Division of Oncology   (Italy)

Author keywords

CDA activity; CDA polymorphism; Cytidine deaminase; Gemcitabine

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE;

BLOOD CELL; BLOOD SAMPLING; CANCER PATIENT; CONFERENCE PAPER; CYTOPLASM; DEAMINATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY;

ANTINEOPLASTIC AGENTS; CYTIDINE DEAMINASE; DEAMINATION; DEOXYCYTIDINE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC;

EID: 46749134759     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770802145447     Document Type: Conference Paper

References (16)

1. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J.L. Pancreatic cancer.Lancet 2004, 363, 1049-1057.
2. Schiller, J.H.; Harrington, D.; Belani, C.P.; et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
3. Eliopoulos, N.; Cournoyer, D.; Momparler, R.L. Drug resistance to 5-za-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother. Pharmacol. 1998, 42, 373-378.
4. Neff, T.; Blau, C.A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 1996, 24, 1340-1346.
5. Bengala, C.. Guarneri, V.; Giovannetti, E.; Lencioni, M.; Fontana, E.; Mey, V.; Fontana, A.; Boggi, U.; Del Chiaro, M.; Danesi, R.; Ricci, S.; Mosca, F.; Del Tacca, M.; Conte, P.F. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br. J. Cancer 2005, 93, 35-40.
6. Ganti, A.K.; Parr, A.; Nguyen, D.; Ganti, A.K.; Parr, A.; Nguyen, D.; Grem, J.L. Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. J. Clin. Oncol. 2006, 24(18S), 2007.
7. Fitzgerald, S.M.; Goyal, R.K.; Osborne, W.R.; Roy, J.D., Wilson, J.W., Ferrell, R.E. Identification of functional single polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 2006, 119, 276-283.
8. Gilbert, J.A.; Salavaggione, O.E.; Yuan, J.; Pelleymounter, L.L.; Eckloff, B.W.; Wieben, E.D.; Ames, M.M.; Weinshilboum, R.M. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 2006, 12, 1794-1803.
9. Kirch, H.-C.; Schroder, J.; Hoppe, H.; Esche, H.; Seeber, S.; Schütte, J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp. Hematol. 1998, 26, 421-425.
10. Yue, L.; Saikawa, Y.; Ota, K.; Tanaka, M.; Nishimura, R.; Uehara, T.; Maeba, H.; Ito, T.; Sasaki, T.; Koizumi, S. A functional single-nucleotide polymorphism in human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003, 13, 29-38.
11. Ruiz van Haperen, V.W.; Veerman, G.; Vermorken, J.B.; Pinedo, H.M.; Peters, G.J. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem. Pharmacol. 1996, 51, 911-981.
12. Bergman, A.M.; Pinedo, H.M.; Jongsma, A.P.; Brouwer, M.; Ruiz van Haperen, V.W.; Veerman, G.; Leyva, A.; Eriksson, S.; Peters G.J. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem. Pharmacol. 1999, 57, 397-406.
13. Sugiyama, E.; Kaniwa, N.; Kim, S.R.; Kikura-Hanajiri, R.; Hasegawa, R.; Maekawa, K.; Saito, Y.; Ozawa, S.; Sawada, J.; Kamatani, N.; Furuse, J.; Ishii, H.; Yoshida, T.; Ueno, H.; Okusaka, T.; Saijo, N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 2007, 25, 32-41.
14. Fukunaga, A.K.; Marsh, S.; Murry, D.J.; Hurley, T.D.; McLeod, H.L. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics. J. 2004, 4, 307-314.
15. Tibaldi, C.; Giovannetti, E.; Vasile, E.; Mey, V.; Laan, A.C.; Nannizzi, S.; Di Marsico, R.; Antonuzzo, A.; Orlandini, C.; Ricciardi, S.; Del Tacca, M.; Peters, G.J.; Falcone, A.; Danesi, R. Correlation of cytidine deaminase, ERCC1 and XPD polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin. Cancer Res. 2008 (in press).
16. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286, 487-491.